July 28, 2024

Cannabis Pharmaceuticals Market to Reach US$ 130.1 Bn by 2030

The global cannabis pharmaceuticals market size was valued at USD 940.5 million in 2020, and is predicted to be worth around USD 130.1 billion by 2030, registering a CAGR of 105.4% during the forecast period 2022 to 2030.

Cannabis Pharmaceuticals

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39112

Cannabis Pharmaceuticals Market  Growth Factors

Rapid growth in applications of cannabis for various indications including pain, inflammation, sleep disorders, anorexia, epilepsy, schizophrenia, and multiple sclerosis is estimated to drive market growth. There is a shift from cannabis herbal preparations to prescription drugs. Demand for processed, quantified, and packaged cannabis products is significantly increasing. Moreover, consumer, as well as regulatory acceptance of cannabis products, is increasing which in turn is positively impacting market growth.

Regulatory acceptance of cannabis products such as Sativex and Epidiolex are improving patient and physician perspectives on cannabis as these drugs are developed and regulated by the stringent process.

The increasing number of research and development activities and clinical trials for studying the therapeutic benefits of cannabis will drive the market growth during the forecast period.

Cannabis Pharmaceuticals Market  Report Coverage
Report Scope Details
Market Size US$ 130.1 billion by 2030
Growth Rate CAGR of 105.4% From 2022 to 2030
Largest Market Europe
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Brand Type
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned GW Pharmaceuticals, plc, Insys Therapeutics, Abbvie, Valeant Pharmaceuticals (Bausch Health Companies, Inc.)
By Brand Type Analysis

The Epidiolex segment dominated the market for cannabis pharmaceuticals accounted for the largest revenue share in 2021 and is estimated to be the fastest-growing segment during the forecast period.

The Sativex segment is estimated to witness a CAGR of 26.9% during the forecast period. Sativex is used to treat muscle spasticity due to multiple sclerosis. Increasing demand for Sativex for use in muscle spasticity in Canada, and European countries are driving the segment growth.

By Regional Analysis

Europe dominated the market for cannabis pharmaceuticals and accounted for the highest revenue share of 43.8% in 2021. This is attributed to increasing cannabis consumption, as well as rising awareness and positive attitude towards cannabis and its products.

Cannabis cultivation in the African region is rapidly growing. Several countries such as Lesotho, South Africa, Malawi, Zambia, Rwanda, and Ghana among others have legalized medical cannabis cultivation. This in turn is estimated to drive the market in the region.

Read also @ Fitness App Market Impressive Gains by 2022-2030

Major Key Players Covered in The Cannabis Pharmaceuticals Market Report include
  • GW Pharmaceuticals, plc
  • Insys Therapeutics
  • Abbvie
  • Valeant Pharmaceuticals (Bausch Health Companies, Inc.)
Cannabis Pharmaceuticals Market  Segmentation
  • By Brand Type
    • Sativex
    • Epidiolex
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Italy
      • France
      • Netherland
      • Poland
      • Croatia
      • Czech Republic
      • Switzerland
    • Asia Pacific
      • Japan
      • South Korea
      • Australia
      • New Zealand
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Columbia
      • Uruguay
      • Chile
      • Peru
    • Middle East & Africa
      • Israel

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Cannabis pharmaceuticals Market, By Brand Type

7.1.  Cannabis pharmaceuticals Market, by Brand Type, 2021-2030

7.1.1.    Sativex

7.1.1.1.        Market Revenue and Forecast (2019-2030)

7.1.2.    Epidiolex

7.1.2.1.        Market Revenue and Forecast (2019-2030)

Chapter 8.  Global Cannabis pharmaceuticals Market, Regional Estimates and Trend Forecast

8.1.  North America

8.1.1.    Market Revenue and Forecast, by Brand Type (2019-2030)

8.1.2.    U.S.

8.1.3.    Rest of North America

8.1.3.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.2.  Europe

8.2.1.    Market Revenue and Forecast, by Brand Type (2019-2030)

8.2.2.    UK

8.2.2.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.2.3.    France

8.2.3.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.2.4.    Rest of Europe

8.2.4.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.3.  APAC

8.3.1.    Market Revenue and Forecast, by Brand Type (2019-2030)

8.3.2.    India

8.3.2.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.3.3.    China

8.3.3.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.3.4.    Japan

8.3.4.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.3.5.    Rest of APAC

8.3.5.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.4.  MEA

8.4.1.    Market Revenue and Forecast, by Brand Type (2019-2030)

8.4.2.    GCC

8.4.2.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.4.3.    North Africa

8.4.3.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.4.4.    South Africa

8.4.4.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.4.5.    Rest of MEA

8.4.5.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.5.  Latin America

8.5.1.    Market Revenue and Forecast, by Brand Type (2019-2030)

8.5.2.    Brazil

8.5.2.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

8.5.3.    Rest of LATAM

8.5.3.1.        Market Revenue and Forecast, by Brand Type (2019-2030)

Chapter 9.    Company Profiles

9.1.  GW Pharmaceuticals, plc

9.1.1.    Company Overview

9.1.2.    Product Offerings

9.1.3.    Financial Performance

9.1.4.    Recent Initiatives

9.2.  Insys Therapeutics

9.2.1.    Company Overview

9.2.2.    Product Offerings

9.2.3.    Financial Performance

9.2.4.    Recent Initiatives

9.3.  Abbvie

9.3.1.    Company Overview

9.3.2.    Product Offerings

9.3.3.    Financial Performance

9.3.4.    Recent Initiatives

9.4.  Valeant Pharmaceuticals (Bausch Health Companies, Inc.)

9.4.1.    Company Overview

9.4.2.    Product Offerings

9.4.3.    Financial Performance

9.4.4.    Recent Initiatives

Chapter 10.  Research Methodology

10.1.              Primary Research

10.2.              Secondary Research

10.3.              Assumptions

Chapter 11.  Appendix

11.1.              About Us

11.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39112

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Leave a Reply

Your email address will not be published. Required fields are marked *